318 filings
Page 5 of 16
8-K
tfk6qmp42 8awxb6uotv
16 Mar 17
Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
12:00am
424B5
hv1c l1gokhnig0zo
15 Mar 17
Prospectus supplement for primary offering
12:00am
424B5
w1d6npiwf8e99mhp
13 Mar 17
Prospectus supplement for primary offering
12:00am
8-K
z2w1y
27 Feb 17
Anthera Pharmaceuticals Provides Business Update
12:00am
8-K
8660r
16 Feb 17
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
65ilxzudt7zis45
6 Jan 17
Regulation FD Disclosure
12:00am
8-K
j41gi9a8aetcvwh it
27 Dec 16
Other Events
12:00am
8-K
cvnka3nh
6 Dec 16
Anthera Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of blisibimod for IgA Nephropathy
12:00am
8-K
bjec3a
1 Dec 16
Regulation FD Disclosure
12:00am
8-K
ap8nmjz90tw3
10 Nov 16
Anthera Announces that the Blisibimod CHABLIS-SC1 Phase 3 Study
12:00am
8-K
f2acsdr
4 Nov 16
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Third Quarter Financial Results
12:00am
S-8
vsukgzk 6d9j3n
4 Oct 16
Registration of securities for employees
12:00am
8-K
4i2g aps0k
15 Sep 16
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
9xxfck
12 Sep 16
Anthera Pharmaceuticals Announces Initial $17.0 Million Closing of a Potential $45.33 Million
12:00am
424B5
xi165o3g pj4qio
8 Sep 16
Prospectus supplement for primary offering
12:00am
8-K
uwtqzjq4p98
16 Aug 16
Anthera Pharmaceuticals Announces Appointment of Dr. William Shanahan Jr. as Chief Medical Officer
12:00am
8-K
i1t6 npk5r267q5w
9 Aug 16
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
12:00am